Hepatitis C Treatment Guide
Quick Reference Guide for Health Care Providers

HCV infection
- Anti-HCV positive
- HCV RNA positive

**History/Physical Exam**
- Prior HCV treatment
- Assess for chronic liver disease, extrahepatic manifestations
- Alcohol, drug use
- Assess need for opioid substitution therapy (OAT)
- Fatty liver disease

**Labs – baseline**
- CBC
- Liver enzymes (ALT/AST/ALP)
- LFT’s (bilirubin, albumin)
- Creatinine
- Fibroscan, if available
- HAV, HBV & HIV status
- Rule out pregnancy

**Fibrosis Assessment**
- Suggestive of cirrhosis:
  - APRI > 1.0; FIB-4 score > 3.25
  - FibroScan > 12.5 kPa
  - Other findings (e.g., nodularity or splenomegaly on imaging)
  - Platelet count <150,000/mm³
  - Prior liver biopsy result
- Minimal fibrosis: APRI<0.7; FIB4 < 1.45

**Do you need to consult with or refer to a specialist? Consider if:**
- Cirrhosis present or suspected
- Prior HCV treatment
- Co-infection with HBV or HIV
- Renal impairment (≥ stage 3: eGFR < 60)
- Known/suspect hepatocellular carcinoma
- Complex drug interactions

**BC Special Authority Forms**

**BC Hep C Network RACE**

**All genotypes, no cirrhosis**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Duration</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAVIRET</td>
<td>8-12 weeks</td>
<td>3 pills/day with food</td>
</tr>
<tr>
<td>Giecaprevir/Pibrentasvir 100mg/400mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPCLUSA</td>
<td>12 weeks</td>
<td>1 pill/day</td>
</tr>
<tr>
<td>Sofosbuvir/Velpatasvir 400mg/100mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**12 weeks post-treatment**
- HCV RNA (SVR-12)
- Liver enzymes and LFT’s

**Treat and manage as per specialist**

- Additional follow-up may include:
  - HCC ultrasound surveillance every 6 months
  - Annual screening for esophageal varices

**Abnormal liver enzymes**
Evaluate for other causes

**No SVR12**
Evaluate for adherence issues, treatment failure or reinfection

**SVR-12 (HCV RNA negative) = CURED!**
- Annual HCV RNA if ongoing risks
- Risk reduction counselling

* Assessment can include: ascites, jaundice, peripheral edema, hepatomegaly, splenomegaly and palmar erythema
Ω Treatment not recommended if pregnant or breast-/chest-feeding

April 2021